Cargando…
Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
AIMS/HYPOTHESES: We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes. METHODS: We performed a case-cohort study (N = 3587), including 655 macrovascular events, 342 mic...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445481/ https://www.ncbi.nlm.nih.gov/pubmed/29728717 http://dx.doi.org/10.1007/s00125-018-4619-x |
_version_ | 1783408204224397312 |
---|---|
author | Welsh, Paul Rankin, Naomi Li, Qiang Mark, Patrick B. Würtz, Peter Ala-Korpela, Mika Marre, Michel Poulter, Neil Hamet, Pavel Chalmers, John Woodward, Mark Sattar, Naveed |
author_facet | Welsh, Paul Rankin, Naomi Li, Qiang Mark, Patrick B. Würtz, Peter Ala-Korpela, Mika Marre, Michel Poulter, Neil Hamet, Pavel Chalmers, John Woodward, Mark Sattar, Naveed |
author_sort | Welsh, Paul |
collection | PubMed |
description | AIMS/HYPOTHESES: We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes. METHODS: We performed a case-cohort study (N = 3587), including 655 macrovascular events, 342 microvascular events (new or worsening nephropathy or retinopathy) and 632 all-cause mortality events during follow-up, in a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study. For this study, phenylalanine, isoleucine, glutamine, leucine, alanine, tyrosine, histidine and valine were measured in stored plasma samples by proton NMR metabolomics. Hazard ratios were modelled per SD increase in each amino acid. RESULTS: In models investigating associations and potential mechanisms, after adjusting for age, sex and randomised treatment, phenylalanine was positively, and histidine inversely, associated with macrovascular disease risk. These associations were attenuated to the null on further adjustment for extended classical risk factors (including eGFR and urinary albumin/creatinine ratio). After adjustment for extended classical risk factors, higher tyrosine and alanine levels were associated with decreased risk of microvascular disease (HR 0.78; 95% CI 0.67, 0.91 and HR 0.86; 95% CI 0.76, 0.98, respectively). Higher leucine (HR 0.79; 95% CI 0.69, 0.90), histidine (HR 0.89; 95% CI 0.81, 0.99) and valine (HR 0.79; 95% CI 0.70, 0.88) levels were associated with lower risk of mortality. Investigating the predictive ability of amino acids, addition of all amino acids to a risk score modestly improved classification of participants for macrovascular (continuous net reclassification index [NRI] +35.5%, p < 0.001) and microvascular events (continuous NRI +14.4%, p = 0.012). CONCLUSIONS/INTERPRETATION: We report distinct associations between circulating amino acids and risk of different major complications of diabetes. Low tyrosine appears to be a marker of microvascular risk in individuals with type 2 diabetes independently of fundamental markers of kidney function. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-018-4619-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users. |
format | Online Article Text |
id | pubmed-6445481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-64454812019-04-17 Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial Welsh, Paul Rankin, Naomi Li, Qiang Mark, Patrick B. Würtz, Peter Ala-Korpela, Mika Marre, Michel Poulter, Neil Hamet, Pavel Chalmers, John Woodward, Mark Sattar, Naveed Diabetologia Article AIMS/HYPOTHESES: We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes. METHODS: We performed a case-cohort study (N = 3587), including 655 macrovascular events, 342 microvascular events (new or worsening nephropathy or retinopathy) and 632 all-cause mortality events during follow-up, in a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study. For this study, phenylalanine, isoleucine, glutamine, leucine, alanine, tyrosine, histidine and valine were measured in stored plasma samples by proton NMR metabolomics. Hazard ratios were modelled per SD increase in each amino acid. RESULTS: In models investigating associations and potential mechanisms, after adjusting for age, sex and randomised treatment, phenylalanine was positively, and histidine inversely, associated with macrovascular disease risk. These associations were attenuated to the null on further adjustment for extended classical risk factors (including eGFR and urinary albumin/creatinine ratio). After adjustment for extended classical risk factors, higher tyrosine and alanine levels were associated with decreased risk of microvascular disease (HR 0.78; 95% CI 0.67, 0.91 and HR 0.86; 95% CI 0.76, 0.98, respectively). Higher leucine (HR 0.79; 95% CI 0.69, 0.90), histidine (HR 0.89; 95% CI 0.81, 0.99) and valine (HR 0.79; 95% CI 0.70, 0.88) levels were associated with lower risk of mortality. Investigating the predictive ability of amino acids, addition of all amino acids to a risk score modestly improved classification of participants for macrovascular (continuous net reclassification index [NRI] +35.5%, p < 0.001) and microvascular events (continuous NRI +14.4%, p = 0.012). CONCLUSIONS/INTERPRETATION: We report distinct associations between circulating amino acids and risk of different major complications of diabetes. Low tyrosine appears to be a marker of microvascular risk in individuals with type 2 diabetes independently of fundamental markers of kidney function. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-018-4619-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2018-05-04 2018 /pmc/articles/PMC6445481/ /pubmed/29728717 http://dx.doi.org/10.1007/s00125-018-4619-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Article Welsh, Paul Rankin, Naomi Li, Qiang Mark, Patrick B. Würtz, Peter Ala-Korpela, Mika Marre, Michel Poulter, Neil Hamet, Pavel Chalmers, John Woodward, Mark Sattar, Naveed Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial |
title | Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial |
title_full | Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial |
title_fullStr | Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial |
title_full_unstemmed | Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial |
title_short | Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial |
title_sort | circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the advance trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445481/ https://www.ncbi.nlm.nih.gov/pubmed/29728717 http://dx.doi.org/10.1007/s00125-018-4619-x |
work_keys_str_mv | AT welshpaul circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial AT rankinnaomi circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial AT liqiang circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial AT markpatrickb circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial AT wurtzpeter circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial AT alakorpelamika circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial AT marremichel circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial AT poulterneil circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial AT hametpavel circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial AT chalmersjohn circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial AT woodwardmark circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial AT sattarnaveed circulatingaminoacidsandtheriskofmacrovascularmicrovascularandmortalityoutcomesinindividualswithtype2diabetesresultsfromtheadvancetrial |